Rapamycin (Sirolimus)

Licensed by Pfizer 製品コードS1039 別名:AY 22989,NSC-2260804

Rapamycin (Sirolimus)化学構造

分子量(MW):914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

サイズ 価格(税別)  
In DMSO JPY 52700
JPY 13600
JPY 46800
JPY 113200
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(217)

製品安全説明書

mTOR阻害剤の選択性比較

生物活性

製品説明 Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
ターゲット
mTOR [1]
(HEK293 cells)
~0.1 nM
体外試験

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 NEHyXHZEgXSxdH;4bYMhSXO|YYm= M3HpTVExKG6P M3jRd|czKGh? NYe3fmdQTE2VTx?= MXzQc5RmdnSrYYTld{Bk[W2ydH;0bIVkcW5vaX7keYNm\CCleYTveI95cWOrdIm= NEPXUWozPDlyMEi3Ny=>
HT-29 MnHKR5l1d3SxeHnjJGF{e2G7 NHH4NWIyOCCwTR?= MlraO|IhcA>? NUDVTo9ZTE2VTx?= M1P2RXBwfGWwdHnheIV{KGSrZ3n0c5hqdi2rbnT1Z4VlKGO7dH;0c5hq[2m2eR?= M2jCOVI1QTByOEez
HT-29 NI\YbHpEgXSxdH;4bYMhSXO|YYm= Mm\PNVAhdk1? M2DlWVczKGh? Ml3CSG1UVw>? NEHh[nVRd3SnboTpZZRmeyB3LX\seY9zd3W{YXPpcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? MkLwNlQ6ODB6N{O=
PC3 NY\ONnRKU2mwYYPlJGF{e2G7 NXHKN2tDOTByIH7N NH;3elIyKGh? MUHEUXNQ MVHQc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gQFExKG6PLh?= NUjmW5ZjOjF7N{i2PFM>
PC3 MUPLbY5ie2ViQYPzZZk> M4jJbVExOCCwTR?= NGT4TXEyKGh? MljwSG1UVw>? MUfEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? MXmyNVk4QDZ6Mx?=
PC3 M{LGdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXFT2JoOS53IN88US=> MoHtNUBp MXLEUXNQ MUPJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RiaIXtZY4hWEN|IHPlcIx{KHerdHigTWM2OCCxZjC8NVAhdk1? NWnoPWg6OjF7N{i2PFM>
HEK293 NVK2PY9mTnWwY4Tpc44hSXO|YYm= NYGzUXNpOTByIH7N M{LNcFghcA>? MnHkSG1UVw>? NWDocllrUW6qaXLpeJMhXFCDLXnu[JVk\WRiZHXndoFl[XSrb36gc4YhWGSlZESge4l1cCCHQ{WwJI9nKDVyIH7N MVqyNVU{QTNyMR?=
BT-20 NGjRb2lMcW6jc3WgRZN{[Xl? Mm\sNlAh|ryP M3LSbWROW09? MoPlSI9meyCwb4SgbY5pcWKrdDDtWG9TSzJiZHXw[Y5l\W62IIDBb3QhWzR5MzDwbI9{eGixconsZZRqd25? NYXROlBIOjF|NUO1OVE>
U937 MXHBcpRq[mGldHXybYFtKEG|c3H5 NUW1cXl5PTBizszN MV[0PEBp M{[3T2ROW09? MljnTY5lfWOnczDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5Qhf2muZDD0fZBmKEynZ3nvcoVtdGFicH7leY1weGirbHGgVIhqdGGmZXzwbIliNTFiSmKzNkBqdiCXOUO3JINmdGy| NVjkeG1zOjFzNEKxNFY>
U937 M1znV2FvfGmkYXP0[ZJq[WxiQYPzZZk> M2OycFUxKM7:TR?= MYW0PEBp NXvRZmZGTE2VTx?= MmDmSI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBOUVBicILveIVqdi2mZX\pZ4lmdnRiTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBLWjN{LUKgbY4hXTl|NzDj[Yxtew>? NY\NSlh[OjFzNEKxNFY>
U937 NWD0WotxSW62aXLhZ5RmemmjbDDBd5NigQ>? MmOzOVAh|ryP Mk\XOFghcA>? MXTEUXNQ MUjEc4V{KG6xdDDpcoR2[2ViYX70bYJi[3SncnnhcEBi[3Srdnn0fUBi\2GrboP0JGV{[2incnnjbIliKGOxbHmgTGIyODFiaX6gWVk{PyClZXzsdy=> MVWyNVE1OjFyNh?=
MCF-7 MmTyRZV1d3CqYXf5JGF{e2G7 Mon2N|Ahdk1? NWPOZ5o5PCCq M{jFfGROW09? NUTx[3dNUW6mdXPld{BifXSxcHjh[5k> NVfUXGYzOjByMkixN|Q>
U87MG NYDvcXlKU2mwYYPlJGF{e2G7 NY[4S21NOSEQvF2= NEPacFA3KGh? NIXVV4xFVVOR NF;BOGxRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbh?= Ml7zNVk5PDh2MES=
U87MG Mm\nT4lv[XOnIFHzd4F6 NHLtdGMyKM7:TR?= NHPZVWY3KGh? NVzqUFNXTE2VTx?= NWDYZmM3WG:2ZX70cJkhcW6qaXLpeJMhPEWEUEGoWFcxMSCyaH;zdIhwenmuYYTpc44> MXixPVg1QDRyNB?=
U87MG NYnGSm1SU2mwYYPlJGF{e2G7 Mo\CNUDPxE1? M33wUFYhcA>? MXTEUXNQ MWrEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? NIK5[HcyQTh2OESwOC=>
U87MG M3\LS2tqdmG|ZTDBd5NigQ>? NGnx[4UyKM7:TR?= Mn;KOkBp MkO3SG1UVw>? MXfEc4V{KG6xdDDpcohq[mm2IGCtOGVDWDFqVEO3M|Q3MSCyaH;zdIhwenmuYYTpc44> NF;GS4MyQTh2OESwOC=>
COS7 cells expressing EGFP-HDQ74/rheb MW\BeZRweGijZ4mgRZN{[Xl? NFHYTFIxNjJizszN NVTSUYlwOjRiaB?= MoPXSG1UVw>? MVPJcoR2[2W|IHH1eI9xcGGpeR?= NWOwZ3RZOTh|OUG5OFk>
COS7 cells expressing EGFP-LC3 NUTSTXNnSXW2b4DoZYd6KEG|c3H5 NHn1b2UxNjJizszN NHn3V40zPCCq NY\UcmdGTE2VTx?= MYnJcoR2[2W|IHH1eI9xcGGpeR?= MVuxPFM6OTl2OR?=
H4 M1joU2Z2dmO2aX;uJGF{e2G7 Mm[yNE4zKM7:TR?= NGW4c3AzPCCq NXrtV5Q6TE2VTx?= NYTZVW5CUW6lcnXhd4V{KHSqZTDyZZRqdyCxZjDsbYdpfCClaHHpckA{KHO3YoXubZQhOiC2bzDsbYdpfCClaHHpckA{KHO3YoXubZQhOSCrbjDoeY1idiCKNDDj[Yxtew>? NYLXO4o4OThyMkS1PFQ>
HeLa MXHGeY5kfGmxbjDBd5NigQ>? MYexNFAhdk1? M2TLelM3KGh? NVfCSXhWTE2VTx?= NFP0dZZKdmS3Y3XzJGZTSiCNMkC5OXAtKFR{MEm4UEwhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v NWDNR4JyOTd3NkOzPFU>
HeLa NH3TV41HfW6ldHnvckBCe3OjeR?= MonaNVAxKG6P MlOyN|YhcA>? MlLESG1UVw>? MnLGTY5lfWOnczDGVmIhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v MVKxO|U3OzN6NR?=
HeLa NVPmd4ZRTnWwY4Tpc44hSXO|YYm= MoO5NVAxKG6P NVnuU2UzOzZiaB?= MljUSG1UVw>? Mmn2TY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;u NXjV[3NLOTd3NkOzPFU>
SYF NYDxbmtwTnWwY4Tpc44hSXO|YYm= M3rSU|ExOCCwTR?= M3jRNFI1KGh? MVHEUXNQ NGqxUnRKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44> NXjXSFRROTd3NkOzPFU>
SYF NE\OdGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWOxNFAhdk1? MXuyOEBp NEHpZ4tFVVOR M3LlRWlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDTXWYh[2WubIO= M16zVVE4PTZ|M{i1
HEK293T M1zX[2FvfGm4aYLhcEBCe3OjeR?= NH60XoIyKG6P MoLPOEBl NEDwe49FVVOR MlHWTY5lfWOnczDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKFJ3IIfpeIghTUN3MDDv[kAxNjFibl2= NVm0bml7OTd2OEW1NFE>
HEK293T M1;qdWFvfGm4aYLhcEBCe3OjeR?= M{TNO|Ehdk1? MkTCOEBl Ml7iSG1UVw>? MYrJcoR2[2W|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhYDRid3n0bEBGSzVyIH;mJFAvOyCwTR?= NU\4VIdkOTd2OEW1NFE>
PBMC M{WwdGZ2dmO2aX;uJGF{e2G7 NEK2dY4yKG6P NYTjfIgzOTRiZB?= Mof3SG1UVw>? NHzvZlBT\WS3Y3XzJGNEWjViZHXud4l1gQ>? Mmj2NVc1QDV3MEG=
PBMC MnvrSpVv[3Srb36gRZN{[Xl? NIXSWJkyKG6P NFLyVZoyPCCm M2fvNGROW09? MWLEc4V{KG6xdDDh[oZm[3RiQ2jDVlQh\GWwc3n0fS=> MVmxO|Q5PTVyMR?=
HEK293 cells M4S4RmtqdmG|ZTDBd5NigQ>? M4eyOlUxKG6P NIHlc5A1PSCvaX6= NVi5dZVPTE2VTx?= MYjJcohq[mm2czDtWG9TKGurbnHz[UBi[3Srdnn0fUB4cXSqIFnDOVAhd2ZiMD6xJI5O M2W5dlE4OzVyOUWz
Drosophila melanogaster S2 cells transfected with N-luc and C-luc NXLBfJhETnWwY4Tpc44hSXO|YYm= Mn;vNVAxKG6P NW\RVI9{PCCq MmqySG1UVw>? MV7JcoR2[2W|IHz1Z4ln\XKjc3WgdJJwfGWrbjD0doFvey2|cHzpZ4lv\yCrbjDEdo9{d3CqaXzhJI1mdGGwb3fhd5RmeiCVMjDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKE5vbIXjJIFv\CCFLXz1Zy=> MYGxO|EzQDJ4Mh?=
Human mixed lymphocyte NWK4dlRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTXXZFtPSCwTR?= MWfEUXNQ NFHF[HNKSzVyPUGuOkBvVS5? M{Lvd|E3OTh3OE[1
Lewis rat lymph node cells MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGi0OYc2KM7:TR?= MV3EUXNQ MnzQTWM2OD1{Lk[g{txO Mn3MNVYyQDV6NkW=
cells from the thymus of normal BALB/c mice NHqwOppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYi0VG5tOTBibl2= NV3CbHg6PzJiaB?= NFOzZpJFVVOR MnXRTY5pcWKrdIOgcJlueGixcILvcIln\XKjdHnvckApVEGIKTD3bZRpKEmFNUCgc4YhOyCwTR?= MoH2NVAxOjF7NEi=
MRK-nu-1 MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7qdpc3UUN3ME2wMlg1PSCyTR?= Ml22V2FPT0WU
OCUB-M M4rHcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3f0XmlEPTB;NT6yOEBxVQ>? M2DEWnNCVkeHUh?=
SF539 NEf3U3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTPOZRIUUN3ME2xNU43KHCP MXLTRW5ITVJ?
ES4 NVztfYlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWm2UHVnUUN3ME2yNU42KHCP NFXvTY1USU6JRWK=
RL95-2 NET0eIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTFyNzDwUS=> NVG5dYI4W0GQR1XS
LC-2-ad M3nFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTR{MzDwUS=> MXTTRW5ITVJ?
Daudi M1TkTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPKcI5KSzVyPUSzOEBxVQ>? MnrZV2FPT0WU
NTERA-S-cl-D1 M2POTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnW3TWM2OD12NEOgdG0> MUDTRW5ITVJ?
OS-RC-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHTfYQ2UUN3ME22OVIheE1? M1PyOXNCVkeHUh?=
VA-ES-BJ MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\2R3NFUUN3ME23NlMheE1? NVv1cJU{W0GQR1XS
GR-ST M{Wxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{njOWlEPTB;OES2JJBO MVTTRW5ITVJ?
SW872 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTh2NjDwUS=> MVHTRW5ITVJ?
NOS-1 M2XrXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\WTWM2OD16N{GgdG0> NF3EPGxUSU6JRWK=
MC116 NYjnb2htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\GTWM2OD17OEWgdG0> MU\TRW5ITVJ?
NCI-H1355 MlXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\CTWM2OD1zLkCxJI5O M{LaUHNCVkeHUh?=
RPMI-8226 MmC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzCTWM2OD1zLkG5JI5O MXHTRW5ITVJ?
TE-15 M4fWS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTFwM{[gcm0> NWnnbVNGW0GQR1XS
Ramos-2G6-4C10 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDiSY1KSzVyPUGuOFYhdk1? MljkV2FPT0WU
KU812 Mn3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3ESGJtUUN3ME2yMlAyKG6P M2r6OXNCVkeHUh?=
EW-1 NIDTeZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vmb2lEPTB;Mj6xO{BvVQ>? NV7qOXJuW0GQR1XS
KS-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\5SGlEPTB;Mj60OUBvVQ>? NWPwVmgzW0GQR1XS
SK-LMS-1 MoHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDWTWM2OD1{LkS5JI5O NHy4[GxUSU6JRWK=
TGBC1TKB MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDSTWM2OD1{Lk[5JI5O NXvXPVZZW0GQR1XS
TE-6 Mn;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfVTWM2OD1{Lke3JI5O MnXjV2FPT0WU
ETK-1 Ml7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrD[XFiUUN3ME2yMlgzKG6P M4TZb3NCVkeHUh?=
BE-13 NIe2dIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr2UHRKSzVyPUKuPVkhdk1? NWDiToROW0GQR1XS
A3-KAW MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFy3fHhKSzVyPUKuPVkhdk1? NFnYbndUSU6JRWK=
TE-10 NWrKbYNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XaeWlEPTB;Mz6zJI5O MWHTRW5ITVJ?
DOHH-2 MnfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jnUGlEPTB;Mz6zOUBvVQ>? Ml6zV2FPT0WU
ES6 M3Ha[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7UdlVKSzVyPUOuOFMhdk1? MXLTRW5ITVJ?
OPM-2 NVq3WJlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33CbGlEPTB;ND6xOUBvVQ>? MoXDV2FPT0WU
SH-4 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkW1TWM2OD12LkO0JI5O NFjvOHFUSU6JRWK=
NB13 Mmj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDnTWM2OD12LkO2JI5O MVnTRW5ITVJ?
HUTU-80 NFOyOGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7ze3hKSzVyPUSuOFIhdk1? NFTJSGhUSU6JRWK=
CCRF-CEM M1;xcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTRwOUSgcm0> MWHTRW5ITVJ?
TGBC24TKB NHKycYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTVwNUGgcm0> NH7jcY1USU6JRWK=
697 NFPTcGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHOTWM2OD14LkK4JI5O MXPTRW5ITVJ?
J-RT3-T3-5 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWX4UoNrUUN3ME22MlQ3KG6P NITMU2tUSU6JRWK=
KALS-1 MoDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTZwNU[gcm0> NIe5c3hUSU6JRWK=
no-10 MkK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPuVFJKSzVyPUeuNlkhdk1? MV7TRW5ITVJ?
SK-NEP-1 Mn7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXS0dHB6UUN3ME24Mlc6KG6P MU\TRW5ITVJ?
L-540 MoTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDiTWM2OD1zMD60NkBvVQ>? NH3selRUSU6JRWK=
JiyoyeP-2003 NYfOXllWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HSO2lEPTB;MUCuPVQhdk1? M3SwZ3NCVkeHUh?=
HH NGnSfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTxTWM2OD1zMT6zPUBvVQ>? MVTTRW5ITVJ?
SR M{DqPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\QfpRKSzVyPUGxMlQ2KG6P NI[zbGNUSU6JRWK=
QIMR-WIL NFG1PFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrJRWM2UUN3ME2xNU45PSCwTR?= NFPYOJlUSU6JRWK=
A4-Fuk M4LabGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlv6TWM2OD1zMz6xNkBvVQ>? MYHTRW5ITVJ?
CESS NHH0fIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTF|LkGzJI5O NF3pUYhUSU6JRWK=
KE-37 M4nMUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPDTWM2OD1zNj6wO{BvVQ>? MVrTRW5ITVJ?
SK-UT-1 MnPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jFS2lEPTB;MU[uPFEhdk1? M2q2NHNCVkeHUh?=
SIG-M5 NUXXZ5l{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\oTWM2OD1zNz6yOUBvVQ>? NVzsc3JJW0GQR1XS
HT M1fWZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXNd3RKSzVyPUG3MlYhdk1? NW\R[WxTW0GQR1XS
DEL NEm1PYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTF5Lkm5JI5O NVfmOWt{W0GQR1XS
SK-PN-DW NHXFUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDpTWM2OD1{MD6yN{BvVQ>? M{XTWnNCVkeHUh?=
RPMI-8402 NWDVfGZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnznTWM2OD1{MT63O{BvVQ>? NHnyRpFUSU6JRWK=
RPMI-6666 M1zmd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWq2O|RGUUN3ME2yOE41OiCwTR?= Ml;KV2FPT0WU
NCI-H720 M2H4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\hSWxWUUN3ME2yOU41OSCwTR?= MWXTRW5ITVJ?
EW-16 NHnmVGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTJ4Lki3JI5O MWPTRW5ITVJ?
BL-70 NIDUeIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[0TWM2OD1{OD6zPEBvVQ>? NVS0[2dGW0GQR1XS
SF126 M2q0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXn0PHBSUUN3ME2zNE4{QCCwTR?= M2[4WHNCVkeHUh?=
BC-1 NFez[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjyeFhMUUN3ME2zNU4zPiCwTR?= MWLTRW5ITVJ?
MHH-PREB-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnG5TWM2OD1|Mj60OEBvVQ>? M1TpXXNCVkeHUh?=
A101D M1nZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjkNJA4UUN3ME2zNk43OiCwTR?= NEHKemFUSU6JRWK=
NMC-G1 M4\yNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI[2bmtKSzVyPUOzMlY4KG6P MoW3V2FPT0WU
LB1047-RCC NGfOcplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTN2Lk[5JI5O MkHrV2FPT0WU
EM-2 MoPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3BTWM2OD1|OD61N{BvVQ>? MYfTRW5ITVJ?
COLO-684 NXPpd2pMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHpTWM2OD1|OT64JI5O M{nuTHNCVkeHUh?=
Becker NGP6VlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULZRlN[UUN3ME20NU4xPSCwTR?= M2CyT3NCVkeHUh?=
BL-41 NUPiTFBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnPTWM2OD12Mz62OkBvVQ>? MUTTRW5ITVJ?
MDA-MB-134-VI NFX0bFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTR2LkCyJI5O NFK5eolUSU6JRWK=
L-363 MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTNOYpKSzVyPUS0Mlc{KG6P MYPTRW5ITVJ?
ECC4 MlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrNXmRKSzVyPUS0Mlc5KG6P NVzpUmJuW0GQR1XS
A388 NG\3VpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYO1ZY9yUUN3ME20OE45OiCwTR?= MXfTRW5ITVJ?
HEL MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELKSohKSzVyPUS5Mlc6KG6P MUnTRW5ITVJ?
RKO MmL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfoNol5UUN3ME21NE4zQSCwTR?= NVXR[FdvW0GQR1XS
KINGS-1 NXPteWZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFX5d3hKSzVyPUWxMlU2KG6P NEO4W2pUSU6JRWK=
EB-3 NXPhVGpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrhSVA{UUN3ME21Nk43PyCwTR?= M{jDR3NCVkeHUh?=
ARH-77 MnnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1X5WmlEPTB;NUKuPEBvVQ>? M3XCUHNCVkeHUh?=
GCIY NHy3V|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTV|LkS2JI5O M3vXPXNCVkeHUh?=
NCI-H1304 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PsWWlEPTB;NUeuNlIhdk1? MkPJV2FPT0WU
KARPAS-299 NEPGPWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoWyTWM2OD14MT64NkBvVQ>? NInO[ZFUSU6JRWK=
IA-LM MkfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVGyPHVzUUN3ME22PE4yOyCwTR?= NHzkblVUSU6JRWK=
GI-1 NHnSO4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWSz[pRLUUN3ME23NE4{QSCwTR?= MWPTRW5ITVJ?
TE-11 M1e4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HId2lEPTB;N{euNVchdk1? NEW2R3NUSU6JRWK=
LS-411N NVzkOItPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTSWYtKSzVyPUe3MlU4KG6P MWfTRW5ITVJ?
no-11 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjiXGdKSzVyPUizMlI1KG6P Mom0V2FPT0WU
MV-4-11 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlH3TWM2OD16Mz63N{BvVQ>? NWnsR4YzW0GQR1XS
BV-173 NFWzS4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnLSGt5UUN3ME24N{46PyCwTR?= Mn7PV2FPT0WU
CMK MnT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn2wTWM2OD16ND6xOkBvVQ>? NX;2Wog{W0GQR1XS
LC4-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4[5OWlEPTB;OE[uO|Ihdk1? NYK3d2hyW0GQR1XS
COR-L279 M3nyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDyb2UxUUN3ME24O{4zPSCwTR?= NXqz[mV{W0GQR1XS
NCI-H209 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;mVWhKSzVyPUi3MlQyKG6P M{TOTHNCVkeHUh?=
Raji NF73fpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGm3[JNKSzVyPUi5MlczKG6P MkHMV2FPT0WU
LB996-RCC Mn;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPaTWM2OD17Mz60N{BvVQ>? MorRV2FPT0WU
NCI-H526 M17YWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHP5emlKSzVyPUmzMlU6KG6P NHr3VYNUSU6JRWK=
KGN Mn;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTl4LkK5JI5O NYr5eW44W0GQR1XS
MOLT-4 NULuZ|V7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYH1W2xkUUN3ME25Ok44QSCwTR?= MX3TRW5ITVJ?
PF-382 NEm3T5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTl4Lke5JI5O NU\TeFN2W0GQR1XS
BC-3 NEPHeIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTl7LkG4JI5O Mn\WV2FPT0WU
KARPAS-422 M322Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnSzTWM2OD1zMEKuNFkhdk1? NHHxXopUSU6JRWK=
SBC-1 NFvSTJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TJS2lEPTB;MUC3Mlc2KG6P MkfiV2FPT0WU
LC-1F MmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HHdmlEPTB;MUC4MlA2KG6P MnvTV2FPT0WU
GB-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHS[mh5UUN3ME2xNFkvODJibl2= M1e1e3NCVkeHUh?=
SNB75 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnYTWM2OD1zMUmuOlkhdk1? Ml3LV2FPT0WU
BB65-RCC MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIO3WZlKSzVyPUGxPU46OyCwTR?= M3\mNXNCVkeHUh?=
NCI-N87 NXTpSIZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTF{MT65PEBvVQ>? MmrBV2FPT0WU
IST-MEL1 NH\jO3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDNTWM2OD1zMkKuN|ghdk1? NYfiPFFiW0GQR1XS
HOP-62 M3\aZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTF{Nj64PUBvVQ>? NV\qUlVkW0GQR1XS
ACN M1TCOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTF2Nj63OUBvVQ>? MnHoV2FPT0WU
DMS-114 NYDLOWxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTtXFRKSzVyPUG1NE43PyCwTR?= NE\ueFFUSU6JRWK=
MLMA NH7jS2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\PSXNKSzVyPUG1PU45QCCwTR?= MXjTRW5ITVJ?
HT-144 NX2wbIIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYi2boJqUUN3ME2xOlUvPDNibl2= Mn7tV2FPT0WU
C2BBe1 M4KwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIP3OFNKSzVyPUG2O{44PiCwTR?= NEfqPJFUSU6JRWK=
L-428 NIDMWnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTF5Nz63JI5O NGq5WmxUSU6JRWK=
DU-4475 M2XYWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTF6Nz62PEBvVQ>? M4rU[HNCVkeHUh?=
CP67-MEL MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\rWVJ3UUN3ME2xPVkvOzhibl2= NFPEb|ZUSU6JRWK=
MEG-01 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\vXGRZUUN3ME2yNFEvQTZibl2= MkLvV2FPT0WU
IST-SL2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEX5epFKSzVyPUKwPE43OyCwTR?= MkjpV2FPT0WU
ES8 NVS4SoZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoX6TWM2OD1{MkWuPVQhdk1? NVzVc2NDW0GQR1XS
COLO-800 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknsTWM2OD1{M{WuNlghdk1? NWnCSm9{W0GQR1XS
MFH-ino NW\0d485T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTJ|NT64OEBvVQ>? MWrTRW5ITVJ?
OVCAR-4 NETkTYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;TWVhvUUN3ME2yN|cvOjRibl2= NX\mbXVLW0GQR1XS
PSN1 M1nzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTJ2Mj63NUBvVQ>? NX3RcoN6W0GQR1XS
EW-12 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTienVtUUN3ME2yOFMvOSCwTR?= NIDxXVdUSU6JRWK=
HCC1599 NEnaRXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTJ4MT60O{BvVQ>? MXLTRW5ITVJ?
SJSA-1 NXHjTG9qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Dk[2lEPTB;MkexMlQ3KG6P MlLCV2FPT0WU
ST486 NHTCUIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofaTWM2OD1{OU[uNVQhdk1? NV;V[GRzW0GQR1XS
NOMO-1 MkTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTNyMD6yNUBvVQ>? NGrONIxUSU6JRWK=
MN-60 M1jM[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\WVHZKSzVyPUOwOU4{OiCwTR?= NV3Ce4ZXW0GQR1XS
HCC1187 NIHQUoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1z5SmlEPTB;M{C3MlI2KG6P NVG1SnRzW0GQR1XS
SW982 NEDRNIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPDTWM2OD1|MUSuO|Uhdk1? M{TQenNCVkeHUh?=
LB647-SCLC MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGf6ZphKSzVyPUOyPE44OSCwTR?= NIr4R3VUSU6JRWK=
HC-1 M{jDUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\V[FBDUUN3ME2zN|UvPSCwTR?= MoPlV2FPT0WU
EHEB MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTN|Nz61NkBvVQ>? MULTRW5ITVJ?
TUR NVzze3RST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\nWGlEPTB;M{[zMlk2KG6P NHrHT4NUSU6JRWK=
LU-139 NH7UTVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXRZXpSUUN3ME2zO|gvODJibl2= NYjVSZFKW0GQR1XS
NB1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnv4TWM2OD1|OESuOFUhdk1? M1PCW3NCVkeHUh?=
BB30-HNC M3vTVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfxXJlKSzVyPUO4PE4{OiCwTR?= NGWw[3FUSU6JRWK=
HAL-01 NV23[IZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTN6OT6yOkBvVQ>? NG\jcI5USU6JRWK=
K5 MlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXtTWM2OD12MUGuN|chdk1? NGf1OmlUSU6JRWK=
MZ2-MEL NHnCR3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PFV2lEPTB;NEGzMlY1KG6P NX\1OXpFW0GQR1XS
RXF393 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWX2R5B6UUN3ME20NVYvPDVibl2= M{HXNnNCVkeHUh?=
NCI-H1648 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTRzNz61N{BvVQ>? M1vTTHNCVkeHUh?=
TE-12 NUKxdphZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37OeGlEPTB;NEO0MlI3KG6P MlTYV2FPT0WU
EoL-1- M1iycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzYTWM2OD12M{euPVghdk1? MVzTRW5ITVJ?
JAR NX;KOINbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDFN5lKSzVyPUSzPE43OiCwTR?= M2TXdnNCVkeHUh?=
DSH1 MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYn1WFZ{UUN3ME20OVgvQTFibl2= MX;TRW5ITVJ?
NCI-H187 M2izeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;wUmlEPTB;NE[yMlgyKG6P NVXOfWdFW0GQR1XS
HCE-4 NU\RU4NoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfZbpNKSzVyPUS3O{43PiCwTR?= NXTnc2ZTW0GQR1XS
8-MG-BA Mlz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHmTWM2OD13OEGuOVIhdk1? M4DtU3NCVkeHUh?=
KLE MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1S3OmlEPTB;NUi1MlIhdk1? NHrZU4JUSU6JRWK=
KNS-42 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILHe5FKSzVyPUW4Ok45OSCwTR?= MnfEV2FPT0WU
MSTO-211H NYO3VphbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzqRmRKSzVyPU[wPU44PCCwTR?= Ml\HV2FPT0WU
GDM-1 MlXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\YWmlEPTB;NkG0MlA6KG6P NFfsVWRUSU6JRWK=
TE-1 M4nQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnezTWM2OD14NE[uNVIhdk1? MV;TRW5ITVJ?
BT-474 M1HzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVezT|lyUUN3ME22OFcvODZibl2= MUHTRW5ITVJ?
KARPAS-45 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnaSHpKSzVyPU[0O{43KG6P MXXTRW5ITVJ?
MOLT-16 MnnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTZ2Nz65N{BvVQ>? MlvaV2FPT0WU
KURAMOCHI NEjVcZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTZ3Nz61NUBvVQ>? MWnTRW5ITVJ?
K-562 Mo\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfHVopQUUN3ME22OlkvPTFibl2= NWfEZlB4W0GQR1XS
EKVX NGW1eo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml:zTWM2OD14N{KuO|Ehdk1? Mlu4V2FPT0WU
GAK NUPWWnFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofyTWM2OD14N{WuN{BvVQ>? NV3RcoZZW0GQR1XS
NCI-SNU-5 M1G5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHpTWM2OD14OUCuNFEhdk1? MYPTRW5ITVJ?
NCI-H2126 NUPEWZBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWD5dI1WUUN3ME23NlYvQDdibl2= MXHTRW5ITVJ?
CTV-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGP1[nZKSzVyPUe0OE46KG6P M1fCeHNCVkeHUh?=
SW962 NYO3fpBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\3NmlEPTB;N{S4MlQ1KG6P NIrodmNUSU6JRWK=
MONO-MAC-6 Mn\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLnTWM2OD15NU[uPVMhdk1? NHSwUZpUSU6JRWK=
NCI-H748 NEHQXINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{H5bmlEPTB;N{W4Mlk6KG6P MlvlV2FPT0WU
NCI-H524 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\ETWM2OD15OECuO|Mhdk1? NEnTbGZUSU6JRWK=
LS-123 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHiRlhKSzVyPUe5OU43QSCwTR?= MlnlV2FPT0WU
NB7 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;2SmlKSzVyPUixOE4yPCCwTR?= NGm1WmxUSU6JRWK=
LS-1034 NHnMOHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrYTWM2OD16MkiuPVghdk1? MV\TRW5ITVJ?
TE-5 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP3UXFKSzVyPUi4N{42PiCwTR?= MVvTRW5ITVJ?
A704 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{C2cGlEPTB;OEm5MlE2KG6P M1POOXNCVkeHUh?=
TK10 M3fXT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7LbY1NUUN3ME25NVYvODNibl2= M3;obnNCVkeHUh?=
NCI-H345 M3L1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1e3XmlEPTB;OUSzMlIzKG6P NGLSW3JUSU6JRWK=
CGTH-W-1 M{LRPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTl2OD6xN{BvVQ>? MWTTRW5ITVJ?
NCI-H510A NEToS4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnId5A3UUN3ME25PFUvOTJibl2= NHvK[3hUSU6JRWK=
NCI-H1963 NInHdmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTFwMEOyPVIh|ryP NEjTOHBUSU6JRWK=
SCC-3 NIPOdm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zFcWlEPTB;MT6wN|QyPCEQvF2= MX;TRW5ITVJ?
EW-11 NI[4bnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XN[mlEPTB;MT6wPFc1OyEQvF2= NWn0WXF6W0GQR1XS
CPC-N MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfDU5VKSzVyPUGuNFg5KM7:TR?= NV\KV5dEW0GQR1XS
NCI-H1417 NHTBU2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTFwMUKyOkDPxE1? MWjTRW5ITVJ?
DG-75 M1LiUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XjfGlEPTB;MT6xOlI5PSEQvF2= M4TCXXNCVkeHUh?=
HD-MY-Z MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDYUphIUUN3ME2xMlE3PDF4IN88US=> M3zGVnNCVkeHUh?=
ATN-1 NX;heFN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHnTWM2OD1zLkK2NlA6KM7:TR?= MlLlV2FPT0WU
KM-H2 M1vRO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7BTWM2OD1zLkK2OFA5KM7:TR?= NGDFcWdUSU6JRWK=
NCI-H2081 NY\6T2pvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTFwMk[2N|ch|ryP NX7wXVlVW0GQR1XS
HL-60 NHT6SoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTFwMk[5OVkh|ryP M{D6VHNCVkeHUh?=
DB M1rXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDqeFQ1UUN3ME2xMlI4OjR{IN88US=> NWLyVHFwW0GQR1XS
NCI-H1522 NXnJ[lhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPETWM2OD1zLkK4PFg4KM7:TR?= MXjTRW5ITVJ?
AM-38 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTNR4NSUUN3ME2xMlMxPzJizszN MULTRW5ITVJ?
NCI-H446 NWK1e3VRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLlTWM2OD1zLkOyNVIyKM7:TR?= NYHoVol3W0GQR1XS
SU-DHL-1 NEj0UWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zZcmlEPTB;MT6zNlgxOSEQvF2= M1vKZ3NCVkeHUh?=
NH-12 MoXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW[ySGxUUUN3ME2xMlM3Ozd2IN88US=> NF7HbHlUSU6JRWK=
DMS-79 MnHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPGPXpKSzVyPUGuN|Y5PjZizszN NYXDfYdxW0GQR1XS
NCI-H716 NE\SXppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfhTlZKSzVyPUGuN|g6QDZizszN NYT6[VlxW0GQR1XS
ML-2 M4[5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTFwNEG1Nlkh|ryP NISx[HpUSU6JRWK=
NB10 NY\vZpJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUX5NFZ3UUN3ME2xMlQ3PjN{IN88US=> MoLoV2FPT0WU
ONS-76 NHTLUWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTFwNUO1Olkh|ryP MV\TRW5ITVJ?
LOUCY M2joRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTFwNUS2OVch|ryP NHjZNXJUSU6JRWK=
SCLC-21H M3HYSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzRTWM2OD1zLkW4OVgzKM7:TR?= MWHTRW5ITVJ?
TGW M1vjRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTFwNkO5O|Uh|ryP NVXzXppYW0GQR1XS
LXF-289 M3yzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTFwN{OyOlgh|ryP MnW5V2FPT0WU
BB49-HNC MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTFwN{O1PFYh|ryP NHfwWWxUSU6JRWK=
NCI-H747 NG\Q[2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWP3WoxxUUN3ME2xMlc2OzR4IN88US=> NYrJbnRsW0GQR1XS
LU-165 M4LKWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFGyS2tKSzVyPUGuPFQ6QDZizszN NVHobpk1W0GQR1XS
OMC-1 M{DsWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXSTWM2OD1zLkm1NFY3KM7:TR?= M17YUXNCVkeHUh?=
RCC10RGB NXWydlVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYCybJFCUUN3ME2xMlk2QDF5IN88US=> MWLTRW5ITVJ?
SW684 NFnZSo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PteWlEPTB;MT65OlA6QSEQvF2= MX\TRW5ITVJ?
TE-8 MkX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7aTmpKSzVyPUKuNFU2PTlizszN NFLETJZUSU6JRWK=
SK-N-DZ M3PCbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGX4bZRKSzVyPUKuNVMzPzRizszN MWfTRW5ITVJ?
EVSA-T MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7XTlNKSzVyPUKuNVc{OTVizszN NFOzOVFUSU6JRWK=
KASUMI-1 M4DpOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrjTWM2OD1{LkG4PFE2KM7:TR?= MXXTRW5ITVJ?
NKM-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTJwMkW0O|Ih|ryP NIjHdWVUSU6JRWK=
CAL-148 M4jTUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHj1UVRKSzVyPUKuN|M3OTRizszN MmDFV2FPT0WU
NCI-H64 M1zScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzmW4pFUUN3ME2yMlM1OjN{IN88US=> NGLJXJZUSU6JRWK=
KNS-81-FD MoTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rwd2lEPTB;Mj6zOlYzKM7:TR?= Mn7CV2FPT0WU
KM12 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLZZ49KSzVyPUKuOFA5OzlizszN NVHvS5dYW0GQR1XS
SW954 MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJwNEe3O|kh|ryP NIT6XmNUSU6JRWK=
NCI-H1395 NGHGdlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vrVGlEPTB;Mj61NlY1PSEQvF2= MoTrV2FPT0WU
DJM-1 NGDZNpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoflTWM2OD1{Lk[wOlMh|ryP MkHZV2FPT0WU
COLO-668 M1flS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILwcYxKSzVyPUKuPFI3QTVizszN M2nG[nNCVkeHUh?=
NCI-H1436 MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;mcmlEPTB;Mj64OVYyPSEQvF2= MU\TRW5ITVJ?
LB2241-RCC Mnj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zhO2lEPTB;Mj64Olg{QSEQvF2= NH;3U4FUSU6JRWK=
GT3TKB NV\MTpR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2X0XmlEPTB;Mj64PVA2PSEQvF2= MlH4V2FPT0WU
COLO-824 NWe5WGtuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzFTWM2OD1{Lki5O|Y5KM7:TR?= MYjTRW5ITVJ?
ES1 M16yXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1u3U2lEPTB;Mj64PVg4QSEQvF2= MoPpV2FPT0WU
LB771-HNC M1HCPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF6xPYhKSzVyPUKuPVA6PDZizszN M{nMdHNCVkeHUh?=
GI-ME-N MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fQUGlEPTB;Mz6wNFkxPCEQvF2= MkTiV2FPT0WU
NALM-6 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfQcWVjUUN3ME2zMlAxQTN|IN88US=> MV;TRW5ITVJ?
LU-134-A NXjYbVZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmW3TWM2OD1|LkC1OFI2KM7:TR?= NYTQR3YzW0GQR1XS
DMS-153 MmD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HGT2lEPTB;Mz6wOVgzPCEQvF2= M{jPeXNCVkeHUh?=
MZ1-PC NHriO4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULUPFQ6UUN3ME2zMlA6ODd6IN88US=> NUfkeJAxW0GQR1XS
NCI-H1155 MmrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLSZYdKSzVyPUOuNVE3OSEQvF2= MXrTRW5ITVJ?
CAS-1 NV3QSWhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTNwMUO3NFch|ryP Mn;XV2FPT0WU
D-502MG MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlG1TWM2OD1|LkG0N|kh|ryP M1rnRXNCVkeHUh?=
NCI-H2141 MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\PRWlEPTB;Mz6xO|Q2OiEQvF2= NGL3NXRUSU6JRWK=
NB6 NFLFNZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH[1PFBKSzVyPUOuNVgzPTlizszN NXr2OIl5W0GQR1XS
NCCIT MoG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTiTWM2OD1|LkKxPFA6KM7:TR?= M163fHNCVkeHUh?=
NB69 M{G2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DK[mlEPTB;Mz6zNVg6OSEQvF2= M1XPd3NCVkeHUh?=
JVM-2 M2XLfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{OxOWlEPTB;Mz6zOlQ{OyEQvF2= MYXTRW5ITVJ?
K052 NVzHemtPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7nTWM2OD1|LkO3PVY5KM7:TR?= MYfTRW5ITVJ?
HCC2157 M2rGZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LtTWlEPTB;Mz61N|IzQCEQvF2= MX3TRW5ITVJ?
KMOE-2 Ml\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHBVHdUUUN3ME2zMlU1OjR{IN88US=> NF\aWnFUSU6JRWK=
SF268 Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkD3TWM2OD1|LkexOVU1KM7:TR?= NGfWbZpUSU6JRWK=
CHP-126 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vo[mlEPTB;Mz63OlQ2QCEQvF2= MoPPV2FPT0WU
CP66-MEL NVHofWFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrUTWM2OD1|Lke5NFk1KM7:TR?= NFnr[oFUSU6JRWK=
NCI-H69 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\aUYlLUUN3ME20MlAyQTN4IN88US=> M1;penNCVkeHUh?=
A253 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTRwMEKxNFEh|ryP MkfiV2FPT0WU
NB14 NGHkOmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTRwMUC0O|kh|ryP NFfnPHRUSU6JRWK=
NCI-H1694 NEnqWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1myeWlEPTB;ND6xN|EyOiEQvF2= MW\TRW5ITVJ?
NCI-H2196 MlnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XwS2lEPTB;ND6xO|E3QSEQvF2= MWfTRW5ITVJ?
TE-9 Mnf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvLTWM2OD12LkG3OVgzKM7:TR?= NYKzTlM2W0GQR1XS
D-283MED NGjZXoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn0bndXUUN3ME20MlE5QDRizszN NYC4NGlrW0GQR1XS
OCI-AML2 M{\tOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknjTWM2OD12LkG5OFg6KM7:TR?= MmHiV2FPT0WU
D-263MG MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TtXWlEPTB;ND6yNlk3OSEQvF2= NVfWTYhbW0GQR1XS
MPP-89 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\ZdWlEPTB;ND6yO|MxPCEQvF2= NV3pVGVOW0GQR1XS
LAMA-84 NGLMd|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFu2V3NKSzVyPUSuN|A1OjFizszN MYrTRW5ITVJ?
LB373-MEL-D NIPTZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIm4[I5KSzVyPUSuN|Y4QDlizszN MV3TRW5ITVJ?
UACC-257 M2DPWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NID5b4JKSzVyPUSuN|k2OzRizszN MVzTRW5ITVJ?
MC-CAR MnPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTRwNEO5PUDPxE1? MkXGV2FPT0WU
COLO-320-HSR NVuzWmFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XZcmlEPTB;ND60OFQzPyEQvF2= NFf1[o1USU6JRWK=
P30-OHK NYX2eZN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLnTWM2OD12Lk[2OVgyKM7:TR?= M1PsNnNCVkeHUh?=
UACC-812 NFHLc3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTRwNkmxOlEh|ryP MnHhV2FPT0WU
CTB-1 NFXYZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4K0cmlEPTB;ND63NVU2PSEQvF2= M4\M[3NCVkeHUh?=
ALL-PO NFy5b2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M120N2lEPTB;ND64OFA4PyEQvF2= MYfTRW5ITVJ?
SK-MEL-2 NX7nXFg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTRwOE[5OVUh|ryP MoOzV2FPT0WU
TC-YIK NYXadVh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnBNFdsUUN3ME20Mlk4QTR{IN88US=> MUTTRW5ITVJ?
NCI-H1882 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTVwMEKwNFEh|ryP MVjTRW5ITVJ?
MHH-CALL-2 MkTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PTSWlEPTB;NT6wOVA1OiEQvF2= NHL2eZNUSU6JRWK=
U-87-MG M{jyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPjSnp{UUN3ME21MlA6PDZ4IN88US=> MVHTRW5ITVJ?
NCI-H1092 NYLVb41GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zjVGlEPTB;NT6yOlU2PSEQvF2= Ml3sV2FPT0WU
TE-441-T NIDEZ|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvhbZNIUUN3ME21MlI4QDJizszN NEX5OXpUSU6JRWK=
SK-MEL-1 NF33ZYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHacYNwUUN3ME21MlI6ODR2IN88US=> M3fqd3NCVkeHUh?=
EW-22 NYrUfmJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4S3TGlEPTB;NT6yPVQ3PiEQvF2= MnL2V2FPT0WU
MZ7-mel MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7WS4FKSzVyPUWuOFA3QTFizszN MX7TRW5ITVJ?
LP-1 M1Tafmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTVwNEGyPVEh|ryP NYj0WnUyW0GQR1XS
NCI-SNU-16 NWrwSW5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonoTWM2OD13Lk[0NFc1KM7:TR?= NITsUnRUSU6JRWK=
LU-65 M1;kVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTVwN{[zO|Mh|ryP NEjpZnFUSU6JRWK=
CW-2 M{TtcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PsNWlEPTB;NT64OVk2QSEQvF2= M1LBRXNCVkeHUh?=
WSU-NHL Ml;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlO2TWM2OD13Lkm1NVc1KM7:TR?= M2W0bHNCVkeHUh?=
IST-MES1 NXTvUI1HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTVwOUW0OFMh|ryP MX\TRW5ITVJ?
U-266 M3i5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37LZmlEPTB;NT65PFIxOiEQvF2= NGPmdFZUSU6JRWK=
TALL-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIH1TVZKSzVyPU[uNVQ3QDhizszN NVXISYZpW0GQR1XS
Calu-6 NFTqXoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TWZWlEPTB;Nj6xOVMyPiEQvF2= MXLTRW5ITVJ?
MMAC-SF MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTZwMUi1OVYh|ryP MnXaV2FPT0WU
NCI-H82 NVzC[4hTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHqdJdTUUN3ME22MlIxPDh7IN88US=> NV;aSpRuW0GQR1XS
RS4-11 MnrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rwdGlEPTB;Nj6yOVg6PyEQvF2= MVfTRW5ITVJ?
SNU-C2B NXnhPGhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXQXmdxUUN3ME22MlQxQTZ7IN88US=> NH;VUlJUSU6JRWK=
BOKU NFvSd|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPUNGNKSzVyPU[uOFc2QTdizszN Mlm2V2FPT0WU
C8166 NEDoOXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTZwNUW5NVIh|ryP M3PpVnNCVkeHUh?=
D-247MG NV75c|JuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTdwMESzOFch|ryP M1W2SnNCVkeHUh?=
EW-18 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1P6WGlEPTB;Nz6wO|I6OiEQvF2= MnLyV2FPT0WU
KG-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXjTWM2OD15Lk[yO|M5KM7:TR?= MkD2V2FPT0WU
REH NYHRWYEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jHW2lEPTB;Nz62PFExQSEQvF2= MmG4V2FPT0WU
U-698-M NVixNHp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoH1TWM2OD15Lki0N|E2KM7:TR?= MonMV2FPT0WU
KP-N-RT-BM-1 M2S5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHMTotKSzVyPUeuPVMxOjlizszN MVjTRW5ITVJ?
MS-1 MmntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37tWWlEPTB;Nz65OlA1OSEQvF2= NU\2UVJCW0GQR1XS
SNU-C1 M{LZOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7aTWM2OD15Lkm4NVkzKM7:TR?= MlvvV2FPT0WU
SK-MM-2 M{HLeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknnTWM2OD16LkK2NFY2KM7:TR?= NGHy[VhUSU6JRWK=
LAN-6 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknQTWM2OD16LkOwNFAyKM7:TR?= Ml20V2FPT0WU
NEC8 NGLzZYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HNPGlEPTB;OD6zNFY6OSEQvF2= M4nTWnNCVkeHUh?=
NCI-H1770 NGPNbnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;FZZBKSzVyPUiuN|gxODJizszN M1L0ZnNCVkeHUh?=
D-336MG M3jLW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRThwNECxNVYh|ryP M1jjcXNCVkeHUh?=
COLO-829 NWDhRZRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moj3TWM2OD16LkS4PFc6KM7:TR?= NWnleYxrW0GQR1XS
LS-513 MoTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRThwNUm1PVkh|ryP NIfCS4FUSU6JRWK=
YT Mlm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWqwOFF1UUN3ME24MlYzPDJ5IN88US=> MVrTRW5ITVJ?
EW-24 M3HBOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHS4d|JKSzVyPUiuO|Y2PCEQvF2= Mn3oV2FPT0WU
IST-SL1 NVS5VodKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nnfWlEPTB;OD64OlU1OyEQvF2= NEPaV|VUSU6JRWK=
CA46 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfodY5KSzVyPUiuPVUxQThizszN M4XH[nNCVkeHUh?=
NCI-H1838 NWj4dG5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DLXGlEPTB;OD65PFYxOiEQvF2= NWPxVZpQW0GQR1XS
NCI-H719 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;JZ2lEPTB;OT6yOVI4QSEQvF2= M1fZRnNCVkeHUh?=
HCE-T MmO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTlwM{C4OVEh|ryP M1nENnNCVkeHUh?=
A498 M1PWTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPSTWM2OD17LkO2NVI1KM7:TR?= MXjTRW5ITVJ?
LB831-BLC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17vRWlEPTB;OT63OlUzOSEQvF2= MmnKV2FPT0WU
SKM-1 M1nvb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHUTWM2OD17Lki1PVY{KM7:TR?= MkjWV2FPT0WU
THP-1 NGXXNGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTlwOU[5NVgh|ryP MlG3V2FPT0WU
SHP-77 NXf5SIEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkC5TWM2OD1zMD60NFch|ryP NVTqPJl6W0GQR1XS
EW-3 NVH2cFdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3WTWM2OD1zMD62Nlg6KM7:TR?= NUHsOmNyW0GQR1XS
KY821 MljsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfsUmlKSzVyPUGwMlc3OyEQvF2= NIXISFRUSU6JRWK=
NCI-SNU-1 M2XGeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTFzLkCyNVch|ryP NWnYXpNFW0GQR1XS
HCC2218 M{e5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml21TWM2OD1zMT6zPVg3KM7:TR?= MoDDV2FPT0WU
IM-9 MmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW[2WGg2UUN3ME2xNU42OTB4IN88US=> MoLJV2FPT0WU
NCI-H889 NUfWUoVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvmcGIzUUN3ME2xNU42OzF|IN88US=> NUC1dpNOW0GQR1XS
HDLM-2 MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;iO5ZOUUN3ME2xNk41OTV7IN88US=> MV7TRW5ITVJ?
LB2518-MEL M2HXUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{m2VmlEPTB;MUKuOlgyPSEQvF2= MonhV2FPT0WU
NCI-H23 NIHjeWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzOeHJLUUN3ME2xN{4zPDJ3IN88US=> MYrTRW5ITVJ?
NB17 NW\SdpVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTF|LkS1O|kh|ryP Mn7VV2FPT0WU
NCI-H322M NWfNR2lYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvnOFZKSzVyPUG0MlQxPjhizszN NYHSNnFjW0GQR1XS
SUP-T1 MnvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4iy[2lEPTB;MUSuOFE{KM7:TR?= NHHlendUSU6JRWK=
ES3 MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF3LkC3NFMh|ryP M3XBRnNCVkeHUh?=
ES5 NHLtTGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDlR4ZKSzVyPUG1MlA4QDdizszN M4S5dHNCVkeHUh?=
NCI-H1650 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoL0TWM2OD1zNT60PVc6KM7:TR?= M1y2dXNCVkeHUh?=
NCI-H226 NWnPPHpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTF3Lki3Olgh|ryP NU\XWIYyW0GQR1XS
COR-L88 NFHlT5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTF4LkOxOEDPxE1? M3LUR3NCVkeHUh?=
SCC-15 Mn73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2S1fmlEPTB;MU[uN|g3QSEQvF2= M3q2SXNCVkeHUh?=
GOTO MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYqybXd4UUN3ME2xOk41Pzl|IN88US=> NVvienJMW0GQR1XS
SIMA MmG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4q3TmlEPTB;MU[uOFgxOiEQvF2= M3HVU3NCVkeHUh?=
NCI-H1299 NVniNlZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXi2XoJ3UUN3ME2xO{4yPTlzIN88US=> M4\LOnNCVkeHUh?=
NCI-H1581 NVHBW29PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7RSYN{UUN3ME2xO{41OjF7IN88US=> NUWyb2RnW0GQR1XS
MHH-NB-11 M1vOdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzUTWM2OD1zNz65Olg{KM7:TR?= M3jJSXNCVkeHUh?=
MFM-223 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTLTWM2OD1zOD6wOVM5KM7:TR?= NXSxbXFzW0GQR1XS
ES7 NVK5fZJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPBd|dKSzVyPUG4MlU1OzFizszN NVTOe4ZJW0GQR1XS
JVM-3 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLLTWM2OD1zOD63NVch|ryP NX3ONIJYW0GQR1XS
RL NIHK[odIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3wO4FKSzVyPUKwMlM5QCEQvF2= MkPXV2FPT0WU
EC-GI-10 NFnoVGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\kW2lEPTB;MkGuNlA1OSEQvF2= MWDTRW5ITVJ?
LNCaP-Clone-FGC NVnqe2pKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrrSXBsUUN3ME2yNU43PzZ6IN88US=> NIT4UmJUSU6JRWK=
IMR-5 NYn1dVdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjUW|VKSzVyPUKxMlg1QTRizszN MmO1V2FPT0WU
KP-N-YS MlXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn2wTWM2OD1{MT64O|Uh|ryP Mn\NV2FPT0WU
Mo-T NGPYWYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTJ{LkKxPFUh|ryP MnixV2FPT0WU
NCI-H128 NHzzcFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rhNmlEPTB;MkOuOVg2OyEQvF2= MYTTRW5ITVJ?
RH-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[0UHRzUUN3ME2yN{44QDZ4IN88US=> NUXEbWtpW0GQR1XS
NCI-H2171 NFXWWZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTJ2LkK0PFUh|ryP M{XNVHNCVkeHUh?=
RPMI-8866 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTJ4Lke0NkDPxE1? MoPHV2FPT0WU
SK-N-FI MkfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TZZWlEPTB;MkeuN|gyOSEQvF2= MX;TRW5ITVJ?
LOXIMVI MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXHTWM2OD1{Nz64NFUyKM7:TR?= Mof2V2FPT0WU
P31-FUJ MnvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\mOWlEPTB;M{GuOVM4PCEQvF2= MlLFV2FPT0WU
KMS-12-PE MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfzcm5KSzVyPUS5MlU{ODJizszN NEnZcGlUSU6JRWK=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
p-mTOR(S2448)/mTOR; 

PubMed: 23991038     


MCF-7-vector and MCF-7-ZNF703 cells were treated with DMSO, 0.1 µM rapamycin, or 1 µM rapamycin for 24 hours before cell lysis. Western blot analysis of lysates using the indicated antibodies. A GAPDH antibody was used as a loading control.

23991038
Growth inhibition assay
Cell proliferation; 

PubMed: 30393233     


(A) Effect of Rapamycin treatment on SK-N-SH cell proliferation. (B) Effect of Rapamycin treatment on SH-SY5Y cell proliferation. Rapamycin, except treatment of 10 µM for 12 h, can obviously inhibited proliferation of NB cells compared with corresponding control group (P<0.05). (*) indicates statistically significant difference with P<0.05.

30393233
Histomorphology
Haematoxylin & Eosin; 

PubMed: 28418837     


Representative pictures of H&E-stained U87MG cells. The fusiform cell body observed in control cells A. disappears in cells exposed to increasing doses of rapamycin for 24 h B.-E. Rapamycin produces a dose-dependent increase in the diameter of the cell body which develops a pyramidal shape. 1 nM (B); 10 nM (C); 100 nM (D); 1 μM (E) of rapamycin exposure.

28418837
Immunofluorescence
NeuN; 

PubMed: 28418837     


Immune-fluorescence of U87MG cells treated with vehicle A.-D. and rapamycin at the dose of 10 nM E.-H.; 100 nM I.-L.; 1 μM M.-P. In the first line cells were stained for the late post-mitotic neuronal marker NeuN. In the second line cells were stained for the nuclear dye DAPI. In the third line the merging between NeuN (green) and DAPI (blue) fluorescence is shown. In the fourth line a high magnification of the squared insert of line three is shown.

p62/Beclin; 

PubMed: 28819214     


(C,D) Rapamycin treatment reduced the aggregate level of p62 and Beclin 1 in cardiomyocytes. NRVCs were transduced with Ad-Nef or Ad-null for 48 hours and cells were fixed with 4% PFA. Fixed cells were stained with p62 and Beclin 1 antibody. 

28418837 28819214
ELISA
Type III collagen/Fibronectin; 

PubMed: 23364979     


(A) Rapamycin inhibits TGF-β1-induced type III collagen level in the culture medium of human lung fibroblast, evidenced by ELISA. Type III collagen level after 24-h incubation with medium alone (control), 0.01, 0.1, 1.0, and 10 ng/mL rapamycin and 10 ng/mL TGF-β1. No significant difference was found between different concentration groups of rapamycin. (B) Rapamycin inhibits TGF-β1-induced fibronectin level in the culture medium of human lung fibroblast, shown by ELISA. Fibronectin level after 24-h incubation with medium alone (control), 0.01, 0.1, 1.0, and 10 ng/mL rapamycin and 10 ng/mL TGF-β1. Values are mean of three independent experiments. No significant difference was found between different concentration groups of rapamycin. *p<0.05 vs. control; †p<0.05 vs. TGF-β1 group. TGF-β1, transforming growth factor β1.

23364979
体内試験 Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
細胞試験:

[3]

+ 展開
  • 細胞株: U87-MG, T98G, and U373-MG
  • 濃度: Dissolved in DMSO, final concentrations ~25 μM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (参考用のみ)
動物試験:

[7]

+ 展開
  • 動物モデル: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • 製剤: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • 投薬量: ~4 mg/kg/day
  • 投与方法: Injection i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 914.18
化学式

C51H79NO13

CAS No. 53123-88-9
保管
in solvent
別名 AY 22989,NSC-2260804

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03866681 Not yet recruiting Paroxysmal Nocturnal Hemoglobinuria Peking Union Medical College Hospital April 1 2019 Phase 4
NCT03454724 Not yet recruiting Coronary Artery Disease Meril Life Sciences Pvt. Ltd. April 1 2019 Not Applicable
NCT03877809 Not yet recruiting Beta-Thalassemia Rare Partners srl Impresa Sociale|Università degli Studi di Ferrara April 1 2019 Phase 2
NCT03866681 Not yet recruiting Paroxysmal Nocturnal Hemoglobinuria Peking Union Medical College Hospital April 1 2019 Phase 4
NCT03454724 Not yet recruiting Coronary Artery Disease Meril Life Sciences Pvt. Ltd. April 1 2019 Not Applicable
NCT03877809 Not yet recruiting Beta-Thalassemia Rare Partners srl Impresa Sociale|Università degli Studi di Ferrara April 1 2019 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

mTORシグナル伝達経路

mTOR Inhibitors with Unique Features

相関mTOR製品

Tags: Rapamycin (Sirolimus)を買う | Rapamycin (Sirolimus) ic50 | Rapamycin (Sirolimus)供給者 | Rapamycin (Sirolimus)を購入する | Rapamycin (Sirolimus)費用 | Rapamycin (Sirolimus)生産者 | オーダーRapamycin (Sirolimus) | Rapamycin (Sirolimus)化学構造 | Rapamycin (Sirolimus)分子量 | Rapamycin (Sirolimus)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID